-
1
-
-
34548457234
-
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours
-
Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2(August (8)):706-714.
-
(2007)
J Thorac Oncol
, vol.2
, Issue.8 AUGUST
, pp. 706-714
-
-
Goldstraw, P.1
Crowley, J.2
Chansky, K.3
Giroux, D.J.4
Groome, P.A.5
Rami-Porta, R.6
-
2
-
-
50849092122
-
European Lung Cancer Working Party Clinical Practice Guidelines: clinical practice guidelines, non-small cell lung cancer: III. Metastatic disease
-
Alexopoulos A., Alard S., Berghmans T., Berchier M.C., Bonduelle Y., Colinet, et al. European Lung Cancer Working Party Clinical Practice Guidelines: clinical practice guidelines, non-small cell lung cancer: III. Metastatic disease. Hospital Chronicles 2008, 1(3):169-185.
-
(2008)
Hospital Chronicles
, vol.1
, Issue.3
, pp. 169-185
-
-
Alexopoulos, A.1
Alard, S.2
Berghmans, T.3
Berchier, M.C.4
Bonduelle, Y.5
Colinet, B.6
-
3
-
-
0030276781
-
The Ontario cancer treatment practice guidelines initiative
-
NOVEMBER (11 Suppl.)
-
Levine M., Browman G., Newman T., Cowan D.H. The Ontario cancer treatment practice guidelines initiative. Oncology (Williston Park) 1996, 10(November (11 Suppl.)):19-22.
-
(1996)
Oncology (Williston Park)
, vol.10
, pp. 19-22
-
-
Levine, M.1
Browman, G.2
Newman, T.3
Cowan, D.H.4
-
4
-
-
1342268525
-
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003
-
Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22(January (2)):330-353.
-
(2004)
J Clin Oncol
, vol.22
, Issue.2 JANUARY
, pp. 330-353
-
-
Pfister, D.G.1
Johnson, D.H.2
Azzoli, C.G.3
Sause, W.4
Smith, T.J.5
Baker, S.6
-
5
-
-
34848849863
-
Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)
-
September (3 Suppl.)
-
Socinski M.A., Crowell R., Hensing T.E., Langer C.J., Lilenbaum R., Sandler A.B., et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(September (3 Suppl.)):277S-289S.
-
(2007)
Chest
, vol.132
-
-
Socinski, M.A.1
Crowell, R.2
Hensing, T.E.3
Langer, C.J.4
Lilenbaum, R.5
Sandler, A.B.6
-
6
-
-
84862302379
-
Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials
-
Yu Y., Xu X., Du Z., Shi M. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials. Cancer Chemother Pharmacol 2012, 69(May (5)):1265-1275.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, Issue.5 MAY
, pp. 1265-1275
-
-
Yu, Y.1
Xu, X.2
Du, Z.3
Shi, M.4
-
7
-
-
84857414572
-
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials
-
Petrelli F., Borgonovo K., Cabiddu M., Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012, 13(March (2)):107-114.
-
(2012)
Clin Lung Cancer
, vol.13
, Issue.2 MARCH
, pp. 107-114
-
-
Petrelli, F.1
Borgonovo, K.2
Cabiddu, M.3
Barni, S.4
-
8
-
-
84866934606
-
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
-
Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13(October (10)):1011-1019.
-
(2012)
Lancet Oncol
, vol.13
, Issue.10 OCTOBER
, pp. 1011-1019
-
-
Camidge, D.R.1
Bang, Y.J.2
Kwak, E.L.3
Iafrate, A.J.4
Varella-Garcia, M.5
Fox, S.B.6
-
9
-
-
84864280988
-
ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis
-
Jiang J., Liang X., Zhou X., Huang R., Chu Z., Zhan Q. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep 2012, 39(June (6)):6933-6942.
-
(2012)
Mol Biol Rep
, vol.39
, Issue.6 JUNE
, pp. 6933-6942
-
-
Jiang, J.1
Liang, X.2
Zhou, X.3
Huang, R.4
Chu, Z.5
Zhan, Q.6
-
10
-
-
84856576940
-
RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis
-
Gong W., Zhang X., Wu J., Chen L., Li L., Sun J., et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012, 75(March (3)):374-380.
-
(2012)
Lung Cancer
, vol.75
, Issue.3 MARCH
, pp. 374-380
-
-
Gong, W.1
Zhang, X.2
Wu, J.3
Chen, L.4
Li, L.5
Sun, J.6
-
11
-
-
34447573875
-
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer
-
Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25(July (19)):2747-2754.
-
(2007)
J Clin Oncol
, vol.25
, Issue.19 JULY
, pp. 2747-2754
-
-
Cobo, M.1
Isla, D.2
Massuti, B.3
Montes, A.4
Sanchez, J.M.5
Provencio, M.6
-
12
-
-
79952539094
-
Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549)
-
Bian H.B., Pan X., Yang J.S., Wang Z.X., De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011, 30:20.
-
(2011)
J Exp Clin Cancer Res
, vol.30
, pp. 20
-
-
Bian, H.B.1
Pan, X.2
Yang, J.S.3
Wang, Z.X.4
De, W.5
-
13
-
-
77957280345
-
Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer
-
Ceppi P., Mudduluru G., Kumarswamy R., Rapa I., Scagliotti G.V., Papotti M., et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010, 8(September (9)):1207-1216.
-
(2010)
Mol Cancer Res
, vol.8
, Issue.9 SEPTEMBER
, pp. 1207-1216
-
-
Ceppi, P.1
Mudduluru, G.2
Kumarswamy, R.3
Rapa, I.4
Scagliotti, G.V.5
Papotti, M.6
-
14
-
-
79959334980
-
MicroRNA gene dosage alterations and drug response in lung cancer
-
Enfield K.S., Stewart G.L., Pikor L.A., Alvarez C.E., Lam S., Lam W.L., et al. MicroRNA gene dosage alterations and drug response in lung cancer. J Biomed Biotechnol 2011, 2011:474632.
-
(2011)
J Biomed Biotechnol
, vol.2011
, pp. 474632
-
-
Enfield, K.S.1
Stewart, G.L.2
Pikor, L.A.3
Alvarez, C.E.4
Lam, S.5
Lam, W.L.6
-
15
-
-
77950203807
-
MiR-181a and miR-630 regulate cisplatin-induced cancer cell death
-
Galluzzi L., Morselli E., Vitale I., Kepp O., Senovilla L., Criollo A., et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010, 70(March (5)):1793-1803.
-
(2010)
Cancer Res
, vol.70
, Issue.5 MARCH
, pp. 1793-1803
-
-
Galluzzi, L.1
Morselli, E.2
Vitale, I.3
Kepp, O.4
Senovilla, L.5
Criollo, A.6
-
16
-
-
80051761550
-
Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP)
-
Wang Q., Zhong M., Liu W., Li J., Huang J., Zheng L. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011, 37(September (7)):427-434.
-
(2011)
Exp Lung Res
, vol.37
, Issue.7 SEPTEMBER
, pp. 427-434
-
-
Wang, Q.1
Zhong, M.2
Liu, W.3
Li, J.4
Huang, J.5
Zheng, L.6
-
17
-
-
80052660944
-
MiR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway
-
Zhang S., Zhang C., Li Y., Wang P., Yue Z., Xie S. miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Biomed Pharmacother 2011, 65(September (6)):436-442.
-
(2011)
Biomed Pharmacother
, vol.65
, Issue.6 SEPTEMBER
, pp. 436-442
-
-
Zhang, S.1
Zhang, C.2
Li, Y.3
Wang, P.4
Yue, Z.5
Xie, S.6
-
18
-
-
77955619456
-
MiR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines
-
Zhu W., Shan X., Wang T., Shu Y., Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, 127(December (11)):2520-2529.
-
(2010)
Int J Cancer
, vol.127
, Issue.11 DECEMBER
, pp. 2520-2529
-
-
Zhu, W.1
Shan, X.2
Wang, T.3
Shu, Y.4
Liu, P.5
-
19
-
-
77955093873
-
MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer
-
Ranade A.R., Cherba D., Sridhar S., Richardson P., Webb C., Paripati A., et al. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol 2010, 5(August (8)):1273-1278.
-
(2010)
J Thorac Oncol
, vol.5
, Issue.8 AUGUST
, pp. 1273-1278
-
-
Ranade, A.R.1
Cherba, D.2
Sridhar, S.3
Richardson, P.4
Webb, C.5
Paripati, A.6
-
20
-
-
84887017002
-
-
WHO handbook for reporting results of cancer treatment. WHO offset publication n°48, Geneva; 1979.
-
WHO handbook for reporting results of cancer treatment. WHO offset publication n°48, Geneva; 1979.
-
-
-
-
21
-
-
0025066941
-
More powerful procedures for multiple significance testing
-
Hochberg Y., Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990, 9(July (7)):811-818.
-
(1990)
Stat Med
, vol.9
, Issue.7 JULY
, pp. 811-818
-
-
Hochberg, Y.1
Benjamini, Y.2
-
22
-
-
79959954361
-
Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival
-
Donnem T., Lonvik K., Eklo K., Berg T., Sorbye S.W., Al-Shibli K., et al. Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 2011, 117(July (14)):3193-3200.
-
(2011)
Cancer
, vol.117
, Issue.14 JULY
, pp. 3193-3200
-
-
Donnem, T.1
Lonvik, K.2
Eklo, K.3
Berg, T.4
Sorbye, S.W.5
Al-Shibli, K.6
-
23
-
-
78650976540
-
Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization
-
Donnem T., Eklo K., Berg T., Sorbye S.W., Lonvik K., Al-Saad S., et al. Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med 2011, 9:6.
-
(2011)
J Transl Med
, vol.9
, pp. 6
-
-
Donnem, T.1
Eklo, K.2
Berg, T.3
Sorbye, S.W.4
Lonvik, K.5
Al-Saad, S.6
-
24
-
-
77950498821
-
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer
-
Hu Z., Chen X., Zhao Y., Tian T., Jin G., Shu Y., et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28(April (10)):1721-1726.
-
(2010)
J Clin Oncol
, vol.28
, Issue.10 APRIL
, pp. 1721-1726
-
-
Hu, Z.1
Chen, X.2
Zhao, Y.3
Tian, T.4
Jin, G.5
Shu, Y.6
-
25
-
-
74549121893
-
MicroRNA expression differentiates histology and predicts survival of lung cancer
-
Landi M.T., Zhao Y., Rotunno M., Koshiol J., Liu H., Bergen A.W., et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010, 16(January (2)):430-441.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.2 JANUARY
, pp. 430-441
-
-
Landi, M.T.1
Zhao, Y.2
Rotunno, M.3
Koshiol, J.4
Liu, H.5
Bergen, A.W.6
-
26
-
-
54049115558
-
Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR
-
Markou A., Tsaroucha E.G., Kaklamanis L., Fotinou M., Georgoulias V., Lianidou E.S. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008, 54(October (10)):1696-1704.
-
(2008)
Clin Chem
, vol.54
, Issue.10 OCTOBER
, pp. 1696-1704
-
-
Markou, A.1
Tsaroucha, E.G.2
Kaklamanis, L.3
Fotinou, M.4
Georgoulias, V.5
Lianidou, E.S.6
-
27
-
-
67651002796
-
MicroRNA classifiers for predicting prognosis of squamous cell lung cancer
-
Raponi M., Dossey L., Jatkoe T., Wu X., Chen G., Fan H., et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009, 69(July (14)):5776-5783.
-
(2009)
Cancer Res
, vol.69
, Issue.14 JULY
, pp. 5776-5783
-
-
Raponi, M.1
Dossey, L.2
Jatkoe, T.3
Wu, X.4
Chen, G.5
Fan, H.6
-
28
-
-
79953327117
-
The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts
-
Saito M., Schetter A.J., Mollerup S., Kohno T., Skaug V., Bowman E.D., et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011, 17(April (7)):1875-1882.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.7 APRIL
, pp. 1875-1882
-
-
Saito, M.1
Schetter, A.J.2
Mollerup, S.3
Kohno, T.4
Skaug, V.5
Bowman, E.D.6
-
29
-
-
80455173422
-
A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis
-
Tan X., Qin W., Zhang L., Hang J., Li B., Zhang C., et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011, 17(November (21)):6802-6811.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.21 NOVEMBER
, pp. 6802-6811
-
-
Tan, X.1
Qin, W.2
Zhang, L.3
Hang, J.4
Li, B.5
Zhang, C.6
-
30
-
-
37349096992
-
MicroRNA signature predicts survival and relapse in lung cancer
-
Yu S.L., Chen H.Y., Chang G.C., Chen C.Y., Chen H.W., Singh S., et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13(January (1)):48-57.
-
(2008)
Cancer Cell
, vol.13
, Issue.1 JANUARY
, pp. 48-57
-
-
Yu, S.L.1
Chen, H.Y.2
Chang, G.C.3
Chen, C.Y.4
Chen, H.W.5
Singh, S.6
-
31
-
-
33644819964
-
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
-
Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9(March (3)):189-198.
-
(2006)
Cancer Cell
, vol.9
, Issue.3 MARCH
, pp. 189-198
-
-
Yanaihara, N.1
Caplen, N.2
Bowman, E.3
Seike, M.4
Kumamoto, K.5
Yi, M.6
-
32
-
-
80053139025
-
MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma
-
Jin L., Hu W.L., Jiang C.C., Wang J.X., Han C.C., Chu P., et al. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci U S A 2011, 108(September (38)):15840-15845.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, Issue.38 SEPTEMBER
, pp. 15840-15845
-
-
Jin, L.1
Hu, W.L.2
Jiang, C.C.3
Wang, J.X.4
Han, C.C.5
Chu, P.6
-
33
-
-
80052102980
-
MiR-149 promotes epithelial-mesenchymal transition and invasion in nasopharyngeal carcinoma cells
-
Luo Z., Zhang L., Li Z., Jiang C., Dai Y., Liu X., et al. miR-149 promotes epithelial-mesenchymal transition and invasion in nasopharyngeal carcinoma cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011, 36(July (7)):604-609.
-
(2011)
Zhong Nan Da Xue Xue Bao Yi Xue Ban
, vol.36
, Issue.7 JULY
, pp. 604-609
-
-
Luo, Z.1
Zhang, L.2
Li, Z.3
Jiang, C.4
Dai, Y.5
Liu, X.6
-
34
-
-
80053347466
-
MiR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer
-
Nishikawa E., Osada H., Okazaki Y., Arima C., Tomida S., Tatematsu Y., et al. miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Res 2011, 71(October (19)):6165-6173.
-
(2011)
Cancer Res
, vol.71
, Issue.19 OCTOBER
, pp. 6165-6173
-
-
Nishikawa, E.1
Osada, H.2
Okazaki, Y.3
Arima, C.4
Tomida, S.5
Tatematsu, Y.6
-
35
-
-
84863075009
-
MiR-375 is highly expressed and possibly transactivated by achaete-scute complex homolog 1 in small-cell lung cancer cells
-
Zhao H., Zhu L., Jin Y., Ji H., Yan X., Zhu X. miR-375 is highly expressed and possibly transactivated by achaete-scute complex homolog 1 in small-cell lung cancer cells. Acta Biochim Biophys Sin (Shanghai) 2012, 44(February (2)):177-182.
-
(2012)
Acta Biochim Biophys Sin (Shanghai)
, vol.44
, Issue.2 FEBRUARY
, pp. 177-182
-
-
Zhao, H.1
Zhu, L.2
Jin, Y.3
Ji, H.4
Yan, X.5
Zhu, X.6
-
36
-
-
84455163058
-
Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma
-
Kinoshita T., Nohata N., Yoshino H., Hanazawa T., Kikkawa N., Fujimura L., et al. Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. Int J Oncol 2012, 40(January (1)):185-193.
-
(2012)
Int J Oncol
, vol.40
, Issue.1 JANUARY
, pp. 185-193
-
-
Kinoshita, T.1
Nohata, N.2
Yoshino, H.3
Hanazawa, T.4
Kikkawa, N.5
Fujimura, L.6
-
37
-
-
84055212101
-
Significance of dysregulated metadherin and microRNA-375 in head and neck cancer
-
Hui A.B., Bruce J.P., Alajez N.M., Shi W., Yue S., Perez-Ordonez B., et al. Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. Clin Cancer Res 2011, 17(December (24)):7539-7550.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.24 DECEMBER
, pp. 7539-7550
-
-
Hui, A.B.1
Bruce, J.P.2
Alajez, N.M.3
Shi, W.4
Yue, S.5
Perez-Ordonez, B.6
-
38
-
-
84863141727
-
Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas
-
Harris T., Jimenez L., Kawachi N., Fan J.B., Chen J., Belbin T., et al. Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 2012, 180(March (3)):917-928.
-
(2012)
Am J Pathol
, vol.180
, Issue.3 MARCH
, pp. 917-928
-
-
Harris, T.1
Jimenez, L.2
Kawachi, N.3
Fan, J.B.4
Chen, J.5
Belbin, T.6
-
39
-
-
83555177355
-
MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor
-
Kong K.L., Kwong D.L., Chan T.H., Law S.Y., Chen L., Li Y., et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012, 61(January (1)):33-42.
-
(2012)
Gut
, vol.61
, Issue.1 JANUARY
, pp. 33-42
-
-
Kong, K.L.1
Kwong, D.L.2
Chan, T.H.3
Law, S.Y.4
Chen, L.5
Li, Y.6
-
40
-
-
79959251756
-
Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection
-
Zhang X., Yan Z., Zhang J., Gong L., Li W., Cui J., et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol 2011, 22(October (10)):2257-2266.
-
(2011)
Ann Oncol
, vol.22
, Issue.10 OCTOBER
, pp. 2257-2266
-
-
Zhang, X.1
Yan, Z.2
Zhang, J.3
Gong, L.4
Li, W.5
Cui, J.6
-
41
-
-
66849140943
-
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
-
Cochrane D.R., Spoelstra N.S., Howe E.N., Nordeen S.K., Richer J.K. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009, 8(May (5)):1055-1066.
-
(2009)
Mol Cancer Ther
, vol.8
, Issue.5 MAY
, pp. 1055-1066
-
-
Cochrane, D.R.1
Spoelstra, N.S.2
Howe, E.N.3
Nordeen, S.K.4
Richer, J.K.5
-
42
-
-
84860261087
-
High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer
-
Liu X.G., Zhu W.Y., Huang Y.Y., Ma L.N., Zhou S.Q., Wang Y.K., et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012, 29(June (2)):618-626.
-
(2012)
Med Oncol
, vol.29
, Issue.2 JUNE
, pp. 618-626
-
-
Liu, X.G.1
Zhu, W.Y.2
Huang, Y.Y.3
Ma, L.N.4
Zhou, S.Q.5
Wang, Y.K.6
-
43
-
-
84863012463
-
Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors
-
Xu Y., Brenn T., Brown E.R., Doherty V., Melton D.W. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer 2012, 106(January (3)):553-561.
-
(2012)
Br J Cancer
, vol.106
, Issue.3 JANUARY
, pp. 553-561
-
-
Xu, Y.1
Brenn, T.2
Brown, E.R.3
Doherty, V.4
Melton, D.W.5
-
44
-
-
79960037044
-
MiR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression
-
Ding D.P., Chen Z.L., Zhao X.H., Wang J.W., Sun J., Wang Z., et al. miR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression. Carcinogenesis 2011, 32(July (7)):1025-1032.
-
(2011)
Carcinogenesis
, vol.32
, Issue.7 JULY
, pp. 1025-1032
-
-
Ding, D.P.1
Chen, Z.L.2
Zhao, X.H.3
Wang, J.W.4
Sun, J.5
Wang, Z.6
-
45
-
-
84855191863
-
The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2
-
Zheng F., Liao Y.J., Cai M.Y., Liu Y.H., Liu T.H., Chen S.P., et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012, 61(February (2)):278-289.
-
(2012)
Gut
, vol.61
, Issue.2 FEBRUARY
, pp. 278-289
-
-
Zheng, F.1
Liao, Y.J.2
Cai, M.Y.3
Liu, Y.H.4
Liu, T.H.5
Chen, S.P.6
-
46
-
-
78650779471
-
Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy
-
Nakashima T., Jinnin M., Etoh T., Fukushima S., Masuguchi S., Maruo K., et al. Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS One 2010, 5(12):e14334.
-
(2010)
PLoS One
, vol.5
, Issue.12
-
-
Nakashima, T.1
Jinnin, M.2
Etoh, T.3
Fukushima, S.4
Masuguchi, S.5
Maruo, K.6
-
47
-
-
79952195451
-
Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer
-
Wang X.C., Du L.Q., Tian L.L., Wu H.L., Jiang X.Y., Zhang H., et al. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer 2011, 72(April (1)):92-99.
-
(2011)
Lung Cancer
, vol.72
, Issue.1 APRIL
, pp. 92-99
-
-
Wang, X.C.1
Du, L.Q.2
Tian, L.L.3
Wu, H.L.4
Jiang, X.Y.5
Zhang, H.6
-
48
-
-
59649093464
-
Evolution of microRNA expression during human bronchial squamous carcinogenesis
-
Mascaux C., Laes J.F., Anthoine G., Haller A., Ninane V., Burny A., et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J 2009, 33(February (2)):352-359.
-
(2009)
Eur Respir J
, vol.33
, Issue.2 FEBRUARY
, pp. 352-359
-
-
Mascaux, C.1
Laes, J.F.2
Anthoine, G.3
Haller, A.4
Ninane, V.5
Burny, A.6
-
49
-
-
84878975723
-
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594
-
Hoang T., Dahlberg S.E., Schiller J.H., Johnson D.H. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. Lung Cancer 2013, 81(July (1)):47-52.
-
(2013)
Lung Cancer
, vol.81
, Issue.1 JULY
, pp. 47-52
-
-
Hoang, T.1
Dahlberg, S.E.2
Schiller, J.H.3
Johnson, D.H.4
|